Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study

Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study

BackgroundImmunogenicity of tumor necrosis factor alpha inhibitors (TNFis) has been recognized as an important problem that may cause loss of efficacy and adverse events such as infusion reactions. TNFis are being increasingly used among patients with Behçet syndrome (BS) and scarce data exist on th...

Full description

Bibliographic Details
Main Authors: Sinem Nihal Esatoglu, Fatma Nihan Akkoc-Mustafayev, Yesim Ozguler, Fatma Ozbakır, Okan K. Nohut, Dilsen Cevirgen, Vedat Hamuryudan, Ibrahim Hatemi, Aykut Ferhat Celik, Hasan Yazici, Gulen Hatemi
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Immunology
Subjects:
infliximab · Remicade
immunogenicity
Behçet disease
drug antibodies
drug level testing
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.618973/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.618973/full

Similar Items